ArticleHaematologica2019
Impact of
Abstract readLetter
In one paragraph
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis.Haematologica · 2022Pooled it
- FLT3-ITD measurable residual disease from the QuANTUM-First trial.Blood advances · 2026Trial
- [Clinical application value of detecting the mutation load of the FLT3-ITD gene before allogeneic hematopoietic stem cell transplantation using PCR-NGS technology].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.Annals of hematology · 2025Article
- Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner.Cancer cell international · 2025Article
- Article
- Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.OncoTargets and therapy · 2025Article
- Understanding the characteristic behaviour of the wild-type and mutant structure of FLT3 protein by computational methods.Computational and structural biotechnology journal · 2025Article
- A double Pólya-Gamma data augmentation scheme for a hierarchical Negative Binomial - Binomial data model.Computational statistics & data analysis · 2024Article
- The Role of FLT3-ITD Mutation, PI3K/AKT Pathway, and Leukemia Stem Cells in D3A7 Induction therapy - the Outcomes of Adult Indonesian Patients with Acute Myeloid Leukemia.Acta medica academica · 2024Article
- Identification of a novel mutation of the FLT3 gene located on the juxtamembrane domain from acute myeloid leukemia patients.Molecular biology reports · 2024Article
- N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants.Bioorganic chemistry · 2024Article
- Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.Blood advances · 2023Article
- Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Article
- Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.Cancers · 2023Review
- How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.Cancers · 2023Review
- An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.Current oncology reports · 2023Review
- ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.BMC bioinformatics · 2023Article
- Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.International journal of hematology · 2022Article
- Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Song-Bai LiuSuzhou Key laboratory for medical biotechnology, Suzhou Vocational Health College, Suzhou, China WSBSL5806@163.com lingli@coh.org slxue@suda.edu.cn.
Hao-Jie DongDepartment of Hematological Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Xie-Bing BaoJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qiao-Cheng QiuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hong-Zhi LiDepartment of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Hong-Jie ShenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zi-Xuan DingJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Chao WangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiao-Ling ChuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jing-Qiu YuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Tao TaoJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zheng LiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiao-Wen TangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Su-Ning ChenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
De-Pei WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ling LiDepartment of Hematological Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA WSBSL5806@163.com lingli@coh.org slxue@suda.edu.cn.
Sheng-Li XueJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China WSBSL5806@163.com lingli@coh.org slxue@suda.edu.cn.
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MTargeting protein acetylation as a therapeutic approach for MDSR01HL141336 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LI, LING · 2018 to 2022
$2.2MResearch career advancement: Role of the SIRT1 deacetylase in maintenance of FLT3R00CA184411 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LI, LING · 2015 to 2017
$747kNCI NIH HHS P30 CA033572NCI NIH HHS R00 CA184411NHLBI NIH HHS R01 HL141336
Abstract
PubMed holds no abstract for this paper.
Indexed as
Mutagenesis, InsertionalAdultDisease-Free SurvivalFemalefms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteMaleSurvival RateFLT3 protein, humanfms-Like Tyrosine Kinase 3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.